Carregant...

Spindle assembly checkpoint inhibition can resensitize p53-null stem cells to cancer chemotherapy

TP53 mutations are common in most human cancers, but few therapeutic options for TP53-mutant tumors exist. To identify potential therapeutic options for cancer patients with TP53 mutations, we profiled 127 FDA approved chemotherapy drugs against human embryonic stem cells (hESC) in which we engineer...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res
Autors principals: Liu, Changlong, Banister, Carolyn E., Buckhaults, Phillip J.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497569/
https://ncbi.nlm.nih.gov/pubmed/30862715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-3024
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!